Gauri Binoy

Is this PBM tactic blocking healthcare access?

/in , , , /by Gauri Binoy
Share on Facebook
Share on Twitter
Share on
LinkedIn
+

Utilization Management (UM) was originally a strategy designed to improve the safety, quality, and cost-effectiveness of physician prescribing. However, UM has grown exponentially over the last decade, becoming more a tactic for Pharmacy Benefit Managers (PBMs) to manage costs to benefit their bottom line. The growth of UM usage has occurred particularly for treatments that address chronic illnesses, which has created many difficulties as patients with serious conditions are now faced with administrative burdens that cause treatment delays ultimately impacting their health outcomes. UM should be reevaluated with a focus on putting patients first.

One of the most common UM strategies is a prior authorization (PA). This tactic requires that patients obtain insurer approval for medicines before they are dispensed, with the initial goals of preventing unnecessary utilization of biopharmaceuticals and decreasing healthcare spending. However, a study conducted by Robert Popovian and Wayne Winegarden investigating the impact of prior authorizations has demonstrated that such schemes increase overall healthcare spending by at least $1.9 billion, primarily imposing these administrative costs on employers, patients, and providers while benefitting PBMs (3).

The question of how UM techniques benefit PBMs is heightened by examining the role of drug rebates. PA is financially beneficial to PBMs on both sides of the equation, as they charge clients for administrative costs of each one and receive rebates from pharmaceutical manufacturers on the underlying prescription. The big question therefore is whether UM is used to ensure that the patient receives the optimal prescription (as its original alleged intent), or mainly for maximizing profit on the PBM side.

The number of PAs only continues to increase. From 2014 to 2020, a study found that the use of PAs increased on commercial plan formularies in nine of twelve major therapeutic areas (including cancer, autoimmune disorders, chronic conditions, and mental health), and restrictions due to UM have increased in all twelve highlighted therapeutic areas (2).

To make matters worse, the 2021 American Medical Association (AMA) PA Physician Survey reported that 73 percent of the imposed PAs are rarely based on medical-based evidence or clinical guidelines, implying that their use is not in the patient’s best interest (1). One of the most significant inefficiencies of prior authorizations are the considerable time delays once requests are submitted. Due to the frequent need for resubmissions, studies have tallied that physicians spend an average of 20 hours helping patients access these medications. Additionally, physicians suffer extra loss by requiring office staff to attend specifically to this (1).

The AMA survey highlighted that in 91 percent of cases, the use of PAs has led to negative clinical outcomes (1). More specifically, 93 percent of those cases have led to delays of which 82 percent of patients do not even follow through on the treatments. Because of these delays, many treatments are altered or stopped (1). Even when treatments are obtained, the final prescribed treatment is often different from the original request due to the inaccessibility of the original prescription, leading to suboptimal care for patients since they often forgo their providers’ prescribed treatment.

These numbers showcase a brutal reality of care inequities masked under the premise of “managing spending”. UM functions to give PBMs unfair ownership over the decision of who gets access to what care.  As a result, in the big picture, these inequitable workflows ultimately determine who will have access to good treatment due to factors outside the patient’s control, leading to poor health outcomes. For this reason, many physicians and patients are calling for a reassessment of UM practices.

Citations

  1. Ama Prior Authorization (PA) Physician Survey. American Medical Association, 2021,

https://www.ama-assn.org/system/files/prior-authorization-survey.pdf

2. Meyer Rebecca Yip Principal Yonatan Mengesha Associate , Tiernan, et al.“Utilization Management Trends in the Commercial Market, 2014–2020.” Avalere Health, 30 Nov. 2021, https://avalere.com/insights/utilization-management-trends-in-the-commercial-market-2014-2020.

3. Popovian R, Winegarden W (2021) An Estimate of the Net Benefits from Prior Authorization Policies in the U.S. Health Sci J. 15 No. 4: 833.

Related Posts:

Opinion: Legislature should act on bill to limit out-of-pocket drug costs

S. 609, a bill that would limit out-of-pocket costs for patients paying for prescription drugs, is a clear step in the right direction. Massachusetts should join 16 other states that have passed similar bills to protect patients.

Opinion: Drug patents aren’t a ‘necessary evil.’ They save lives.

Drug patents are one of the most important public policy innovations in all of human history, and a boon to patients awaiting cures. Inventions only come when inventors are rewarded, not punished. Patents are not a “necessary evil.”

Study: High List Prices and Deep Discounts for Prescription Drugs Hurt Poor and Sick Patients

A new Pioneer Institute study illustrates how the current system of drug pricing and discounts leads to patients with challenging diseases being charged huge out-of-pocket sums to keep other premiums low, effectively imposing financial penalties on the sick to protect the healthy and wealthy.

A Federal Drug Discount Program for the Wealthy

The combination of legal disputes, a growing data repository and investigative reports have necessarily put the 340B Drug Pricing Program under the microscope. Combined with the fact that the policy lacks transparency, 340B has spiraled out of control to the point that no policymaker can ignore the need to look closer.

First-of-Its-Kind Interactive Mapping Tool Reveals Extent of For-Profit Entities Benefitting from the 340B Drug Pricing Program

Today, Pioneer Institute released a first-of-its-kind, 50-state mapping tool and database highlighting the troubling way in which hospitals and covered entities leverage unlimited pharmacy contracts under the 340B Drug Pricing Program.

Harvard research points to ending drug cost help

A common grievance about Harvard is that the university is out of touch with the concerns of everyday Americans. This perception is confirmed by recent research from Harvard Business School that contends patients should be denied assistance that helps them afford their prescription drugs. The Harvard study argues that in order to control drug prices, the government should deny patients’ access to copay assistance programs offered by drug manufacturers. It flies in the face of federal and state efforts to protect the value of such assistance programs for patients and ignores basic facts about how and when patients use copay assistance to access their medications.

Massachusetts Hospitals Pull Back on Charity Care as Revenue from Federal 340B Drug Discount Program Explodes

Over the past decade, the revenue for hospitals generated by the federal 340B drug discount program, initially intended to serve low-income, uninsured populations, has exploded even while a number of important Massachusetts hospitals have reduced the level of charity care they provide, according to a new study published by Pioneer Institute. The Pioneer Institute study, “340B Drug Discounts: An Increasingly Dysfunctional Program,” notes that nationwide, 340B drug sales rose from $9 billion in 2014 to $38 billion in 2020.

The Promise and Challenges of Rare Cancer Treatments

Dr. William Smith, Pioneer Institute's Visiting Fellow in Life Sciences, spoke about the challenges and opportunities for rare cancer treatments, in a video interview produced by Rare Cancers, a patient group based in Australia, for the November 26th CAN Forum. 

Study: Decline in Cardiovascular Health Screenings During COVID-19 Pandemic Poses New Public Health Threat

Pioneer Institute today released a new analysis focused on cardiovascular disease, An “Impending Tsunami” in Mortality from Traditional Diseases?, that examines how the COVID-19 pandemic has created another unrelated public health crisis. The Pioneer analysis examines how a single-minded public health focus on COVID-19, social distancing, and lockdowns drove reductions in screenings, diagnoses, and early treatment for complex conditions such as heart disease.

A Modest Proposal to Raise Federal Revenue

As a way to tackle drug prices, President Joe Biden recently announced that he supports the so-called “inflation rebate,” which would require drug companies to give the federal government any revenue from Medicare drug prices above the general rate of inflation. Senate Finance Committee Chairman Ron Wyden and House Speaker Nancy Pelosi have also publicly endorsed the inflation rebate.